A first-in-class inhibitor of HSP110 to potentiate XPO1-targeted therapy in primary mediastinal B-cell lymphoma and classical Hodgkin lymphoma
Manon Durand(Inserm), Gaëtan Jégo(Inserm)
Cited by 7
Related Papers
Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation
|Biochemical and Biophysical Research Communications|2020|16